製品番号: HY-13442

Eribulin

(別名: B1939; E7389; ER-086526)

8 Cited Publications

カスタマーレビュー

Based on 8 publication(s) in Google Scholar

Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.46%
CAS 番号: 253128-41-5
分子式: C₄₀H₅₉NO₁₁
分子量:729.90

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Eribulin 構造式

CAS 番号: 253128-41-5

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (8)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

ADC Payloads アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
DLD-1	IC₅₀	13 nM Compound: 56	Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth incubated for 3 to 4 days Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth incubated for 3 to 4 days	[PMID: 39068862]
DLD-1	IC₅₀	20 nM Compound: 1	Cytotoxicity against human DLD1 cells Cytotoxicity against human DLD1 cells	[PMID: 21324692]
DLD-1	IC₅₀	20 nM Compound: eribulin	Antiproliferative activity against human DLD1 cells assessed as growth inhibition Antiproliferative activity against human DLD1 cells assessed as growth inhibition	[PMID: 21324686]
HCT-15	IC₅₀	204 nM Compound: 1	Cytotoxicity against human HCT15 cells Cytotoxicity against human HCT15 cells	[PMID: 21324692]
HCT-15	IC₅₀	204 nM Compound: eribulin	Antiproliferative activity against human HCT15 cells assessed as growth inhibition Antiproliferative activity against human HCT15 cells assessed as growth inhibition	[PMID: 21324686]
MES-SA	IC₅₀	1.66 nM Compound: 1	Cytotoxicity against human MES-SA cells Cytotoxicity against human MES-SA cells	[PMID: 21324692]
MES-SA	IC₅₀	1.66 nM Compound: eribulin	Antiproliferative activity against human MES-SA cells assessed as growth inhibition Antiproliferative activity against human MES-SA cells assessed as growth inhibition	[PMID: 21324686]

体外実験

Eribulin (1-100 nM; 72 h) inhibits cells proliferation, with IC₅₀s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively^[1].
Eribulin (10-50 nM; 12-72 h) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells^[1].
Eribulin (10-50 nM; 12-72 h) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells^[1].
Eribulin (1-50 nM; 12 h) does not induce senescence in LM8 cells^[1].
Eribulin (1-10 nM; 16 h) induces morphological change and suppresses cell migration in a low concentration in LM8 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

LM8 cells and Dunn cells
Concentration:

0, 1, 10, 100 nM
Incubation Time:

72 hours
Result:

Inhibited cells proliferation in a dose-dependent manner.

Apoptosis Analysis^[1]

Cell Line:

LM8 cells
Concentration:

0, 10, 50 nM
Incubation Time:

12, 24, 48, 72 hours
Result:

Induced early apoptosis after 12 h at the concentration of 50 nM.
Not detected apoptosis at the concentration of 10 nM.

Cell Cycle Analysis^[1]

Cell Line:

LM8 cells
Concentration:

0, 10, 50 nM
Incubation Time:

12, 24, 48, 72 hours
Result:

Induced G2/M arrest by 12 h treatment with 50 nM.
No G2/M arrest was induced by10 nM treatment.

体内実験

Eribulin (1 mg/kg; i.v. once a week for 2 weeks) reduces primary tumor growth and lung metastasis of osteosarcoma in mice^[1].
Eribulin (1 mg/kg; once i.v.) suppresses circulating tumor cells (CTC) appearance in the low-concentration phase^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C3H/HeN mice (4-week-old) are injected LM8 cells^[1]
Dosage:

1 mg/kg
Administration:

I.v. once a week for 2 weeks
Result:

Suppressed primary tumor growth and induced apoptosis in tumor cells. Reduced lung metastasis.
Decreased the body weights.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 253128-41-5
性状 Solid
分子量 729.90
分子式 C₄₀H₅₉NO₁₁
Color White to off-white
SMILES

C=C1C[C@@](CC[C@@]2(C[C@@]3([H])O4)O[C@]([C@](O[C@](C5)([H])CC6)([H])[C@@]6([H])O7)([H])[C@@]4([H])[C@]7([H])[C@@]3([H])O2)([H])O[C@@]1([H])CC[C@](C[C@@H](C)C8=C)([H])O[C@]8([H])C[C@@](O[C@H](C[C@H](O)CN)[C@@H]9OC)([H])[C@]9([H])CC5=O
別名

B1939; E7389; ER-086526
輸送条件

Shipping with dry ice.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (8)

All Histological Imaging/StainingCell Proliferation/Viability AssayApoptosis AnalysisIn Vivo Efficacy StudyCell Imaging/Staining

Sort by:

Journal Impact Factor

Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
J Control Release

Improved biodistribution and antitumor effects of a Nectin4 and Trop2 bispecific fatty acid-modified nanobody conjugate. [Abstract]

2025 Oct 14;388(Pt 1):114325. PMID: 41101697
Dev Cell

KIF2C promotes paclitaxel resistance by depolymerizing polyglutamylated microtubules. [Abstract]

2025 Mar 25:S1534-5807(25)00151-0. PMID: 40157365

Eribulin purchased from MedChemExpress. Usage Cited in: Dev Cell. 2025 Mar 25:S1534-5807(25)00151-0. [Abstract]

Eribulin (0-2¹⁰ nM; 72 h). Cell viability of 4T1 S1, R4, and R8 cells following treatments of Eribulin for 72 h.
NPJ Breast Cancer

Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay. [Abstract]

2025 Feb 17;11(1):17. PMID: 39962055

Eribulin purchased from MedChemExpress. Usage Cited in: NPJ Breast Cancer. 2025 Feb 17;11(1):17. [Abstract]

Eribulin (1 nM; 72 h). Microscopic images of EdU (pink) and DAPI (blue) channels for two selected models: HBCx-4B and HBCx-39.

Eribulin purchased from MedChemExpress. Usage Cited in: NPJ Breast Cancer. 2025 Feb 17;11(1):17. [Abstract]

Eribulin (1 nM; 72 h). Quantification of HBCx-4B and HBCx-39 TUNEL staining. Each data point represents quantification of the percentage of cells in apoptosis within one microscopic field of view; ten fields of view were analyzed per condition in triplicate.

Eribulin purchased from MedChemExpress. Usage Cited in: NPJ Breast Cancer. 2025 Feb 17;11(1):17. [Abstract]

Eribulin (0.4 mg/kg; IV). Results of the in vivo eribulin treatment of the HBCx-137 PDX model, representing the measurements of the tumor size in mm3 over the time in culture.

Eribulin purchased from MedChemExpress. Usage Cited in: NPJ Breast Cancer. 2025 Feb 17;11(1):17. [Abstract]

Eribulin (1 nM; 72 h). Representative images of the pH3- (green) and EdU-positive (pink) cells with and without Eribulin treatment for the HBCx-137 PDX model (Eribulin-sensitive in vivo).
mBio

KSHV and HPV modulate epithelial-to-mesenchymal transition in oral epithelial cells. [Abstract]

2025 Aug 15:e0048425. PMID: 40815147
Molecules

Small Molecules Identified by an In Silico Docking Screen Targeting Anaphase-Promoting Complex/Cyclosome Subunit 1 (APC1) Potentiate Paclitaxel-Induced Breast Cancer Cell Death. [Abstract]

2025 Feb 14;30(4):895. PMID: 40005207
iScience

Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. [Abstract]

2022 Sep 6;25(10):105081. PMID: 36204272
Res Sq

2024 Sep 17.

溶剤 & 溶解度

体外:

DMSO : 200 mg/mL (274.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3701 mL

6.8503 mL

13.7005 mL

5 mM

0.2740 mL

1.3701 mL

2.7401 mL

10 mM

0.1370 mL

0.6850 mL

1.3701 mL

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (6.85 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (6.85 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (6.85 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (284 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10(2): 161-174. [Content Brief]

[2]. Okouneva, T., et al., Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008. 7(7): p. 2003-11. [Content Brief]

[3]. Smith, J.A., et al., Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry, 2010. 49(6): p. 1331-7. [Content Brief]

[4]. Towle, M.J., et al., Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res, 2011. 71(2): p. 496-505. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.3701 mL	6.8503 mL	13.7005 mL	34.2513 mL
	5 mM	0.2740 mL	1.3701 mL	2.7401 mL	6.8503 mL
	10 mM	0.1370 mL	0.6850 mL	1.3701 mL	3.4251 mL
	15 mM	0.0913 mL	0.4567 mL	0.9134 mL	2.2834 mL
	20 mM	0.0685 mL	0.3425 mL	0.6850 mL	1.7126 mL
	25 mM	0.0548 mL	0.2740 mL	0.5480 mL	1.3701 mL
	30 mM	0.0457 mL	0.2283 mL	0.4567 mL	1.1417 mL
	40 mM	0.0343 mL	0.1713 mL	0.3425 mL	0.8563 mL
	50 mM	0.0274 mL	0.1370 mL	0.2740 mL	0.6850 mL
	60 mM	0.0228 mL	0.1142 mL	0.2283 mL	0.5709 mL
	80 mM	0.0171 mL	0.0856 mL	0.1713 mL	0.4281 mL
	100 mM	0.0137 mL	0.0685 mL	0.1370 mL	0.3425 mL

Eribulin

8 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Eribulin

Toxins for Antibody-Drug Conjugate Research Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

MedChemExpress（MCE）の使用を引用している文献 Eribulin

ADC Payloads アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (8)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Eribulin

Toxins for Antibody-Drug Conjugate Research Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

MedChemExpress（MCE）の使用を引用している文献 Eribulin

ADC Payloads アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (8)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Eribulin 関連分類

HY-13442 関連分類